|
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma
|
5R44CA199767-02
|
$659,861
|
$659,861
|
SMITH, CHARLES
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs)
|
5R44CA203221-02
|
$687,200
|
$687,200
|
HUPERT, MATEUSZ
|
BIOFLUIDICA, INC
|
|
Sensitivity of multiple myeloma cells to mTOR inhibitors
|
4R01CA111448-10
|
$184,270
|
$184,270
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S1
|
$1,595,651
|
$39,891
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S2
|
$550,000
|
$13,750
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S3
|
$750,000
|
$18,750
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-03
|
$9,068,022
|
$226,701
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Diet patterns, aspirin use, obesity and multiple myeloma: a prospective analysis
|
5R21CA198239-02
|
$202,245
|
$202,245
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
PET Scan for Prognostication in Newly Diagnosed High Risk Multiple Myeloma
|
1R01CA201634-01
|
$177,133
|
$177,133
|
USMANI, SAAD
|
CAROLINAS MEDICAL CENTER
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S1
|
$20,833
|
$1,042
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S2
|
$60,000
|
$3,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S3
|
$118,406
|
$5,920
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S4
|
$200,000
|
$10,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
4P30CA043703-26
|
$4,895,515
|
$244,776
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-03
|
$1,033,213
|
$25,830
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental Co
|
5R01CA138688-08
|
$312,294
|
$312,294
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
A novel T-cell subset able to kill relapsed cancers
|
1R01CA200539-01A1
|
$362,569
|
$362,569
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma
|
4R01CA163881-06
|
$395,129
|
$395,129
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5R00CA172292-04
|
$248,999
|
$248,999
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Validating Rapid Microfluidic Isolation of Personalized Aptamers for Monitoring Minimal Residual Disease in Multiple Myeloma
|
1R33CA196470-01A1
|
$394,518
|
$394,518
|
LIN, QIAO
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cancer Center Support Grant
|
3P30CA013696-42S1
|
$120,000
|
$3,600
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S2
|
$60,000
|
$1,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S3
|
$121,873
|
$3,656
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S4
|
$150,866
|
$4,526
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S5
|
$199,541
|
$5,986
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S6
|
$500,000
|
$15,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-42
|
$3,792,720
|
$113,782
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-02
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of MMP13 in Multiple Myeloma Bone Disease
|
5R01CA175313-03
|
$331,098
|
$331,098
|
LENTZSCH, SUZANNE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
|
1R01CA207237-01
|
$395,166
|
$395,166
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
SPORE in Multple Myeloma
|
4P50CA100707-14
|
$2,162,000
|
$2,162,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-24
|
$301,545
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S1
|
$122,500
|
$2,450
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S2
|
$37,500
|
$750
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S3
|
$125,000
|
$2,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S4
|
$200,000
|
$4,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S5
|
$60,000
|
$1,200
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S6
|
$199,953
|
$3,999
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S7
|
$500,000
|
$10,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-51S8
|
$750,000
|
$15,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
4P30CA006516-51
|
$11,151,311
|
$223,026
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
|
1R50CA211399-01
|
$264,110
|
$66,028
|
BIRD, GREGORY
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-03
|
$1,106,869
|
$27,672
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Validating the eCyPA/CD147 signaling complex for myeloma therapy
|
5R01CA196783-02
|
$394,823
|
$394,823
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INST
|
|
Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
|
4R01CA160979-05
|
$363,125
|
$181,563
|
FRANK, DAVID
|
DANA-FARBER CANCER INST
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
1R01CA205954-01
|
$438,499
|
$438,499
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
5R01CA181683-03
|
$353,773
|
$353,773
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Development and Application of Selective Covalent Cdk7 Inhibitors
|
5R01CA179483-03
|
$501,164
|
$501,164
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
|
Functional and biologic significance of deacetylase3 inhibition in myeloma
|
5R01CA178264-03
|
$353,291
|
$353,291
|
HIDESHIMA, TERU
|
DANA-FARBER CANCER INST
|
|
Determining the mutational landscape of circulating multiple myeloma cells
|
5K08CA191026-02
|
$177,120
|
$177,120
|
LOHR, JENS
|
DANA-FARBER CANCER INST
|
Total relevant funding to Multiple Myeloma for this search: $52,066,811
|